Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. / Bader, Jakob Maximilian; Deigendesch, Nikolaus; Misch, Martin; Mann, Matthias; Koch, Arend; Meissner, Felix.

In: Cell Reports Medicine, Vol. 4, No. 1, 100877, 2023.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bader, JM, Deigendesch, N, Misch, M, Mann, M, Koch, A & Meissner, F 2023, 'Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status', Cell Reports Medicine, vol. 4, no. 1, 100877. https://doi.org/10.1016/j.xcrm.2022.100877

APA

Bader, J. M., Deigendesch, N., Misch, M., Mann, M., Koch, A., & Meissner, F. (2023). Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. Cell Reports Medicine, 4(1), [100877]. https://doi.org/10.1016/j.xcrm.2022.100877

Vancouver

Bader JM, Deigendesch N, Misch M, Mann M, Koch A, Meissner F. Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. Cell Reports Medicine. 2023;4(1). 100877. https://doi.org/10.1016/j.xcrm.2022.100877

Author

Bader, Jakob Maximilian ; Deigendesch, Nikolaus ; Misch, Martin ; Mann, Matthias ; Koch, Arend ; Meissner, Felix. / Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status. In: Cell Reports Medicine. 2023 ; Vol. 4, No. 1.

Bibtex

@article{1536444008044cecbe2f16fde4b5c77a,
title = "Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status",
abstract = "High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in combined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q codeletion status. Glioma proteome alterations remain undercharacterized despite their promise for a better molecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread perturbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma proteome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.",
author = "Bader, {Jakob Maximilian} and Nikolaus Deigendesch and Martin Misch and Matthias Mann and Arend Koch and Felix Meissner",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2023",
doi = "10.1016/j.xcrm.2022.100877",
language = "English",
volume = "4",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status

AU - Bader, Jakob Maximilian

AU - Deigendesch, Nikolaus

AU - Misch, Martin

AU - Mann, Matthias

AU - Koch, Arend

AU - Meissner, Felix

N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2023

Y1 - 2023

N2 - High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in combined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q codeletion status. Glioma proteome alterations remain undercharacterized despite their promise for a better molecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread perturbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma proteome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.

AB - High-grade adult-type diffuse gliomas are malignant neuroepithelial tumors with poor survival rates in combined chemoradiotherapy. The current WHO classification is based on IDH1/2 mutational and 1p/19q codeletion status. Glioma proteome alterations remain undercharacterized despite their promise for a better molecular patient stratification and therapeutic target identification. Here, we use mass spectrometry to characterize 42 formalin-fixed, paraffin-embedded (FFPE) samples from IDH-wild-type (IDHwt) gliomas, IDH-mutant (IDHmut) gliomas with and without 1p/19q codeletion, and non-neoplastic controls. Based on more than 5,500 quantified proteins and 5,000 phosphosites, gliomas separate by IDH1/2 mutational status but not by 1p/19q status. Instead, IDHmut gliomas split into two proteomic subtypes with widespread perturbations, including aerobic/anaerobic energy metabolism. Validations with three independent glioma proteome datasets confirm these subgroups and link the IDHmut subtypes to the established proneural and classic/mesenchymal subtypes in IDHwt glioma. This demonstrates common phenotypic subtypes across the IDH status with potential therapeutic implications for patients with IDHmut gliomas.

U2 - 10.1016/j.xcrm.2022.100877

DO - 10.1016/j.xcrm.2022.100877

M3 - Journal article

C2 - 36584682

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

SN - 2666-3791

IS - 1

M1 - 100877

ER -

ID: 331589871